Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
10 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
08 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM WILMETTE, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a...
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
12 nov. 2020 09h15 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Clinical Trial on Track to Start Before Year-endIssuance of New Patents For ValidiveCamsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12,...
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
09 nov. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
14 sept. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
09 sept. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
19 août 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit,...
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
12 août 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
10 août 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
06 août 2020 16h05 HE
|
Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...